|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||216.40 - 224.70|
|52-week range||170.36 - 248.30|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||79.32|
|Forward dividend & yield||1.72 (0.79%)|
|Ex-dividend date||22 Nov 2021|
|1y target est||N/A|
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The ongoing integration of Cantel Medical business and robust demand from medical device customers are expected to have contributed to STERIS' (STE) Q3 performance.
Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.